RespireRx Pharmaceuticals Inc (RSPI)

[in2it]

Somee Curiousnes about CSA

A couple potentially complicating and/or compelling informational pieces about CSA.

One is that the prevalence, although something less than 10% of sleep disturbed patients, rises considerably among those having medically significant circumstances, eg. 25-40% of heart failure patients. Thus, the treatment course is not necessarily a single pathway.

Also, the incidence varies almost farcically across national populations... the solution to that puzzle will no doubt be part of a successful treatment.